Collectively, these observations not only identify G2/M-associated phosphorylation at S64 as a critical determinant of the antiapoptotic activity of Mcl-1, but also elucidate a novel mechanism by which CDK1/2 inhibitors can enhance the effectiveness of the cytotoxic cytokine TRAIL.
Mcl-1 is an antiapoptotic
Collectively, these observations not only identify G2/M-associated phosphorylation at S64 as a critical determinant of the antiapoptotic activity of Mcl-1, but also elucidate a novel mechanism by which CDK1/2 inhibitors can enhance the effectiveness of the cytotoxic cytokine TRAIL.
INTRODUCTION
The Bcl-2 family member Mcl-1 promotes cell viability at a critical upstream point in the apoptotic cascade (1) .
Mcl-1 and other antiapoptotic members of this family (Bcl-2, Bclx L , A1 and Bcl-w) interrupt cell death signals by binding to pro-apoptotic family members (e.g., Bim, Noxa and others in the case of Mcl-1) (2) (3) (4) (5) . A distinctive characteristic of Mcl-1 is its short half life [approximately 2 -4 hours in various cell types (6) (7) (8) ], which probably relates to the presence of a long proline-, glutamic acid-, serine-, and threonine-rich (PEST) 1 region upstream of the Bcl-2 homology domains (9) (10) (11) .
Alterations that affect Mcl-1 expression can have severe, potentially detrimental consequences. Conditional deletion of Mcl-1 results in bone marrow failure in mice due to apoptosis of precursor cells (12) (13) (14) . Conversely, forced
Mcl-1 overexpression predisposes hematopoietic cells to malignant transformation (15) . In addition, enhanced Mcl-1 expression has been observed in multiple human cancers, often in association with poor prognosis, disease recurrence, or drug resistance (7, (16) (17) (18) (19) (20) (21) . Thus, the mechanisms that regulate Mcl-1 play an important role both in controlling cell survival in normal tissues and in preventing the emergence of tumors.
Mcl-1 expression is regulated at the transcriptional and post-translational levels. The transcription factors SRF/ETS, STAT3, CREB, and PU.1 have been found to regulate Mcl-1 gene expression in various cell types (22) (23) (24) (25) (26) . At the post-translational level, Mcl-1 is targeted for proteasomal degradation after ubiquitylation by an E3 ligase termed MULE (11) . This susceptibility of Mcl-1 to degradation is phosphorylationdependent.
In particular, ERK-mediated phosphorylation of Mcl-1 at T163 within the PEST region prolongs the Mcl-1 half-life (6) . In contrast, following T163 phosphorylation, S159 phosphorylation by GSK-3β reportedly enhances Mcl-1 ubiquitylation and degradation (8) . Consistent with the latter results, Akt inhibition, which activates GSK-3β, results in Mcl-1 downregulation (7) . Mcl-1 is also downregulated by inhibitors of CDK9, which diminish its synthesis (20, 27, 28) .
Mcl-1 phosphorylation is also known to be stimulated at other, as-yet-unidentified sites during G2/M phase of the cell cycle (29). This phosphorylation is prominent in cells accumulating in G2/M phase upon exposure to microtubule disrupting agents, and is also seen in synchronized cells passing through this phase. Bcl-2, the prototypic member of this family, likewise undergoes phosphorylation at multiple sites, one of which is stimulated during G2/M phase (30) (31) (32) (33) (34) (35) . Phosphorylation of Bcl-2 can affect its stability and/or antiapoptotic function, with differing effects being reported in different systems. For example, phosphorylation of Bcl-2 at T69, S70, and S87 was associated with both enhanced antiapoptotic activity and slowed turnover in cells (35) . In the case of Mcl-1, JNKmediated phosphorylation on S121 has been reported to sensitize cells to oxidative stressinduced cell death apparently without affecting turnover (36) . Thus, phosphorylation may affect the function as well as its turnover of Mcl-1.
The present studies were performed to identify additional phosphorylation sites in Mcl-1 distinct from the T163 and S159 sites that influence turnover. These studies demonstrated that Mcl-1 phosphorylation on S64, which is catalyzed by CDK1, CDK2 or JNK1 in vitro, is increased in G2/M phase of the cell cycle and contributes to the antiapoptotic activity of Mcl-1 by enhancing it's binding to proapoptotic Bcl-2 family members rather than altering its expression. Consistent with these results, a CDK inhibitor that blocked S64 phosphorylation also sensitized cells to TRAIL-mediated apoptosis.
Thus, while phosphorylation at T163/S159 regulates Mcl-1 turnover, a distinct pathway involving phosphorylation at S64 regulates its anti-apoptotic function.
EXPERIMENTAL PROCEDURES
Materials. The CDK inhibitor SU9156 (37) was from Alexis (San Diego, CA). The MEK inhibitors (U0126, PD98059), the p38 MAPK inhibitor SB220025, the JNK inhibitor SP600125 the GSK-3ß inhibitor BIO (GSK inhibitor IX, (2'Z, 3'E)-6-bromoindirubin-3'-oxime), the CDK 2/5 inhibitor PNU 112455A (N 4 -(6-aminopyrimidin-4-yl)-sulfanilamide), the CDK inhibitors olomoucine and roscovitine, and the proteasome inhibitor MG-132 were from Calbiochem (La Jolla, CA).
Cell Lines and Culture. The human cholangiocarcinoma cell line KMCH-1 was cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin G (100,000 U/l), streptomycin (100 mg/l), and gentamicin (100 mg/l) as described previously (38) . The KMCH cell line stably transfected with Mcl-1-shRNA (designated KMCH-shMcl-1) was cultured in medium supplemented with 400 mg/l G418 as previously described (20) .
In situ phosphorylation assay. Polypeptides were recovered after radiolabeling based on S peptide-S protein interactions (39) . KMCH cells, and KMCH cells stably transfected with S peptide-tagged versions of wild type, T163A, and S64A Mcl-1 were incubated with or without [ 32 P] phosphate (50 µCi/ml) plus MG-132 (10 µM) for 6 hours. At the end of the labeling, cells were washed in PBS and lysed in lysis buffer consisting of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM α-phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM Na 3 VO 4 , 100 mM NaF, 20 nM microcystin, and 1% Triton X-100. After the protein concentration was estimated using the Bradford method (40), aliquots containing 1 mg of protein in 1 ml of lysis buffer were incubated with 50 µl of S-protein agarose beads (Novagen, La Jolla, CA) at 4 °C overnight. After at least 6 washes with lysis buffer, samples were released from the beads by boiling for 5 min in 50 µl of Laemmli sample by guest on November 15, 2017 http://www.jbc.org/ Downloaded from buffer (Bio-Rad Laboratories, Hercules, CA, USA) containing 5% 2-mercaptoethanol. Samples were resolved by SDS-PAGE, and transferred to nitrocellulose membranes.
Radioactivity was determined by autoradiography using a phosphorimager (Molecular Dynamics, Sunnyvale, CA) at room temperature for 3-6 days. T 163 and S 64 specific phosphorylations were detected by immunoblotting using phospho-epitope specific antibodies as described below. Phosphorylation site analysis. KMCH cells stably transfected with S peptide-tagged T163A Mcl-1 were cultured in 10 cm dishes. After cells were solubilized in lysis buffer, S peptide-tagged T163A Mcl-1 was recovered on S protein-agarose as previously described (39 MN) ; monoclonal rat antiBim S antibody (14A8) at 1:500 from Chemicon (Temecula, CA); polyclonal rabbit anti-Bax antibody at 2 µg/ml and polyclonal rabbit anti-Bak NT at 2 μg/ml from Upstate (Lake Placid, NY); polyclonal goat anti-DR5 antibody at 1:200 and polyclonal rat anti-cFLIP antibody at 1:200 from Alexis (San Diego, CA); and polyclonal rabbit anti-DR4 antibody at 1:500 (Axxora, San Diego, CA). Monoclonal mouse anti-S peptide antibody was generated as previously described (39) . Affinity-purified rabbit antiserum recognizing the Mcl-1 T 163 phospho-epitope generated by Cell Signaling Technology (Beverly, MA) was used at 1:500.
Production and purification of rabbit polyclonal anti-phospho-S64-Mcl-1 phosphospecific antiserum. A 15-amino acid peptide (Mcl-1 amino acids 57-71) with a phospho-serine at position 64 and an N-terminal cysteine was synthesized by Mayo Clinic Proteomics Core. After conjugation to keyhole-limpet hemocyanin, the peptide was utilized to immunize rabbits according to standard procedures.
To permit affinity purification of serum, the immunizing peptide and its nonphosphorylated counterpart were individually conjugated to SulfoLinkSepharose (Pierce, Rockford, IL) according to supplier's protocol. Immune serum was then passed sequentially over columns containing the unphosphorylated and phosphorylated peptides; and purified antibodies were eluted from the second column with glycine (pH 2.2). Proteincontaining fractions were dialyzed into PBS with 0.02% sodium azide and concentrated using Centriprep YM-30 centrifugal filters (Millipore, Bedford, MA). Purified antibodies were stored at -80°C. Dot blot analysis was employed to examine the specificity of the affinity purified antisera for the phosphorylated peptide. Bovine serum albumin-conjugated peptides with phosphorylated or unphosphorylated serine 64 were serially diluted into a dot blot apparatus and detection performed as described above under immunoblot analysis.
Detection of Mcl-1 phosphorylation at S64. Because the phospho-specific anti-Mcl-1 (S64) antibody generated does not yield a reliable signal on immunoblot of total protein lysates, enrichment of Mcl-1 was necessary. For analysis of the endogenous Mcl-1 phosphorylation, Mcl-1 was immunoprecipitated from parental KMCH cells using a polyclonal anti-Mcl-1 antibody (S19), followed by immunoblot analysis for total (S19) or S64-phosphorylated Mcl-1. For KMCH cells transfected with the S peptide-tagged Mcl-1 mutants (see below), protein-S agarose purification was used to recover tagged Mcl-1 prior to immunoblot analysis.
In vitro phosphorylation assays. Plasmid encoding GST-Mcl-1 was generated by subcloning Mcl-1 lacking the transmembrane domain into the commercially available pGEX-4T-1 vector (GE healthcare, Piscataway, NJ). BL21 cells transformed with the plasmid were cultured in 10 ml of Circlegrow (Q-BIOgene, Carlsbad, CA) plus ampicillin (100 μg/ml) until the optical density at 600 nm reached 0.8-1.5. Cells were then induced with 1 mM IPTG for 3 hours at 37 °C. Harvested cells were lysed with BugBuster® (Novagen, La Jolla), benzonase, lysozyme, and protease inhibitor cocktail II (Calbiochem, La Jolla, CA) for 20 min; and transferred into a glutathione-agarose column under gravity flow. After washing with GST bind/wash buffer (Novagen, La Jolla, CA), the bound protein was eluted with glutathione (Novagen, La Jolla, CA). The elution buffer was exchanged to the corresponding kinase buffer (New England Biolabs, Ipswich, MA) and the protein was concentrated using Centriprep YM-30 centrifugal concentrators (Millipore, Bedford, MA). The protein concentration was measured by the Bradford assay (40) . In vitro kinase assays were performed by incubating GST-Mcl-1 protein with CDC2 (CDK1) plus cyclin B or CDK2 plus cyclin A (New England Biolabs, Ipswich, MA) in the presence of 1 mM ATP for 30 min at 30 °C. After the reaction was terminated with SDS sample buffer, samples were resolved by 10% SDS-PAGE, transferred to nitrocellulose and probed with anti-phospho-S64 Mcl-1 antiserum to detect the phosphorylated species. Equal loading of GST-Mcl-1 was verified by blotting for total Mcl-1.
For JNK phosphorylation studies, BL21 cells were lysed as above and clarified by centrifugation. Glutathione agarose (100 μL of 50% slurry) was then added to 1 mL of supernatant and mixed end-over-end at 4ºC overnight. The glutathione agarose bound to GSTMcl-1 was harvested by centrifugation, washed six times in bind/wash buffer, and rinsed one time with kinase buffer. GST-Mcl-1 still bound to glutathione agarose was used as a substrate for JNK1α1 (Cell Signaling Technologies, Beverly, MA) or JNK2α2 (Calbiochem, La Jolla, CA) under conditions suggested by the respective suppliers. After 30 min at 30ºC, the reaction was stopped by the addition of SDS sample buffer. Samples were boiled and resolved by 12% SDS-PAGE, transferred to nitrocellulose and probed with anti-phospho-S64 Mcl-1 antiserum to detect the phosphorylated species. Equal loading of GST-Mcl-1 was verified by blotting for total Mcl-1.
Site-directed mutagenesis. pcDNA3.1 containing the full-length Mcl-1 cDNA has been previously described (41) . A 15-amino acid S peptide tag (KETAAAKFERQHMDS) with GA linker (total 28 amino acids) was inserted at the Nterminus of Mcl-1 essentially as described (39) . Plasmid encoding the S peptide-tagged Mcl-1 was then subjected to site-directed mutagenesis to generate S peptide-tagged T163A, S64A and S64E mutants using the QuickChange II XL SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the supplier's instructions. To allow expression of the S peptide-tagged variants in cells expressing Mcl-1 shRNA, the wildtype and mutant tagged Mcl-1 cDNAs were rendered shRNA resistant by silent mutation of the third nucleotides in four of the targeted codons to the sequence cgggactggctagttaaac using the same site-directed mutagenesis kit. Finally, for stable transfection, the cDNAs were subcloned into pcDNA 3.1 Hygro(+) (Invitrogen, Carlsbad, CA, USA). All plasmids were subjected to automated sequencing to verify the described mutation and confirm that no additional mutations were present. These plasmids were prepared for transfection using a plasmid miniprep kit (Bio-Rad, Hercules, CA, USA).
Generation of KMCH stable transfectants. Transfection was performed using LipofectAMINE (Invitrogen, Carlsbad, CA, USA). Stably transfected clones were selected in medium containing 1200 mg/l G418 or both G418 plus 200 mg/l hygromycin.
Individual colonies were isolated using cloning rings, subcloned and screened by immunoblotting. Established clones were maintained in medium supplemented with 400 mg/l G418 and/or 200 mg/l hygromycin.
Mcl-1 half-life estimation. KMCH cells stably expressing shRNA to the endogenous Mcl-1 and stably expressing S peptide-tagged Mcl-1 constructs (described above) were treated for a total of 4 hours with vehicle or TRAIL. During this treatment, 20 µg/ml cycloheximide was added for 0-120 min. At the end of the incubation, floating cells were collected by centrifugation added to adherent cells, and lysed, followed by addition of SDS sample buffer in preparation for SDS-PAGE and transfer to nitrocellulose. After blots were probed with anti-Mcl-1 and anti-actin antibodies, signals were detected and quantified using an Odyssey fluorescent imager as described above.
Exponential trend lines from three independent experiments were calculated using Microsoft Excel (Microsoft Office, Microsoft, Redmond, WA, USA). Half-life was determined by the formula t 1/2 =ln(2)/λ, where λ is the decay constant.
Determination of Mcl-1-binding partners. KMCH cells expressing siRNAresistant S peptide-tagged mutant (S64A or S64E) and siRNA against endogenous Mcl-1 were solubilized in lysis buffer containing 1% CHAPS in place of Triton X-100. Tagged Mcl-1 was pulled down using S protein-agarose. Pelleted proteins were solubilized in SDS sample buffer, clarified by centrifugation, separated by electrophoresis, and probed using antibodies to the indicated Bcl-2 family members.
Measures of TRAIL-induced cytotoxicity in KMCH cells. After treatment with TRAIL as indicated in the various figure legends, apoptosis was quantitated by identifying the characteristic nuclear changes of apoptosis (i.e., chromatin condensation and nuclear fragmentation) using the nuclear binding dye DAPI and fluorescence microscopy. To assess changes in caspase 3/7 activity, cells plated in 96-well plates were assayed using the commercially available Apo-ONE homogenous caspase 3/7 assay (Promega Corp, Madison, WI), which measures cleavage of profluorescent rhodamine 110-conjugated bis-(N-benzyloxycarbonyl-Laspartyl-L-glutamyl-L-valyl-aspartic acid amide) to liberate rhodamine 110, according to the supplier's instructions using excitation and emission wavelengths of 498 and 521 nm, respectively.
Cell synchronization and cell cycle analysis. KMCH cells stably transfected with S peptide-tagged Mcl-1 were arrested in mitosis by treatment with nocodazole (40 ng/ml), and at the G1/S boundary by treatment with aphidicolin (10 µM) for 16 hours. Confirmation of the cell cycle effects of the drugs was obtained by flow cytometric analysis.
Briefly, after treatment, trypsinized cells were collected, washed with PBS twice, fixed with 50% ethanol, rinsed with PBS, treated with RNase A (100 µg/ml) at 37 °C for 10 min, and stained with propidium iodide (100 µg/ml) for 5 min. Cell cycle distribution was assessed using a FACSan (Becton Dickinson, Mountain View, CA). The Modfit LT for Mac version 3.0 (Verity Software House, Topsham, ME,) was used to estimate the percentage of cells in various phases of the cell cycle.
Statistical analysis. Statistical analysis was performed using a Student's t test from at least three independent experiments.
RESULTS
Mcl-1 is phosphorylated at S64. Previous studies have suggested that phosphorylation of Mcl-1 on T163 and S159 can influence the half-life and, therefore, the expression level and antiapoptotic effects of this polypeptide. To assay for Mcl-1 phosphorylation at additional sites, we initially compared the metabolic labeling of Mcl-1 by [
32 P] phosphate in cells expressing S peptide-tagged versions of wild type or T163A Mcl-1. Because phosphorylation of T163 is required for S159 phosphorylation, neither T163 nor S159 can be phosphorylated in the T163A mutant (8), effectively allowing us to abrogate phosphorylation at both sites with one mutation. When the tagged polypeptides were recovered from cells by affinity purification on S protein-agarose (39), resolved by SDS-PAGE and subjected to autoradiography as well as immunoblotting (Fig. 1) , phospho-T163-Mcl-1 epitope-specific antiserum specifically labeled wildtype Mcl-1 but not the T163A mutant, whereas 32 P labeled both species. These results suggested that Mcl-1 is phosphorylated on one or more residues in addition to T163 and S159.
To further identify these phosphorylation sites, microgram quantities of unlabeled S peptide-tagged Mcl-1 163A were affinity purified from exponentially growing cells, subjected to SDSpolyacrylamide gel electrophoresis, and excised from the gel. Trypsin digestion followed by Qtof-MS/MS identified a previously unknown phosphorylation site S64 (Fig. 2A) . Further analysis demonstrated that S64, which is within a "poor" PEST sequence upstream from the PEST sequence that contains T163 and S159, is conserved through a wide range of species (Fig.  2B ) including dog and cat. Interestingly, the rodent Mcl-1 (both mouse and rat) contains an acidic glutamic acid at this residue, which could function as a constitutive phosphomimetic. In addition, S64 is a serine-proline site that conforms to several consensus kinase motifs (http://scansite.mit.edu/motifscan_seq.phtml and http://www.cbs.dtu.dk/services/NetPhos/). Given this information, we focused our efforts on the potential role of S64 phosphorylation in Mcl-1 regulation.
CDKand JNK1-induced S64 phosphorylation in vitro. To facilitate further analysis, we generated and characterized a phosphoepitope-specific antiserum against the peptide surrounding S64. As illustrated in Fig.  3A , dot blot analysis demonstrated that affinitypurified aliquots of this serum recognized the phosphorylated-S64 peptide against which it was raised much more avidly than the corresponding unphosphorylated polypeptide. This serum was then utilized to determine whether S64 is phosphorylated in situ and to assess the effects of various kinase inhibitors.
Initial experiments with this serum examined whether endogenous Mcl-1 was phosphorylated at S64 under basal conditions and in the presence of the proteasome inhibitor MG132, which increases cellular levels of Mcl-1 (Fig. 3B) . Based on computer analysis suggesting that Mcl-1 might be phosphorylated on S64 by GSK3ß, ERK, p38 MAPK, JNK, CDK5, and/or CDK1, cells were treated with inhibitors of these kinases and harvested for immunoblotting. To avoid an effect of these inhibitors on Mcl-1 transcription, the studies were performed in KMCH stably transfected with Mcl-1 shRNA and shRNA-resistant S peptide-tagged Mcl-1, which was under the control of a CMV promoter and, therefore, not subject to the usual transcriptional regulation of the Mcl-1 promoter. Analysis of the immunoblots demonstrated a >20-fold stronger signal with the anti-phospho-S64 antiserum when cells were expressing wildtype Mcl-1 as compared to S64A Mcl-1 (Fig. 3C) , confirming the specificity of the serum in the setting of whole cell lysates. Moreover, this analysis revealed that exposure to the CDK inhibitor SU9516 (which is known to inhibit CDK 1, 2 and 5) substantially diminished S64 phosphorylation (Fig. 3C) . A reduction in phosphorylation was also observed with the JNK inhibitor (SP600125). In contrast, inhibitors of MEK1/2 (PD98059, U0126), p38 MAPK (SB220025) and GSK3ß (BIO), did not inhibit phosphorylation. PNU112455A, which inhibits predominantly CDK5, likewise did not diminish S64 phosphorylation. To confirm the effects of the CDK inhibitor SU9516 on S64 phosphorylation, phosphoimmunoblot analysis was also performed in cells treated with the less selective CDK inhibitors olomoucine and roscovitine. Treatment with these agents also reduced S64 phosphorylation, with roscovitine being more potent than olomoucine, consistent with their known affinities for CDKs (42) .
To more directly determine whether S64 can be phosphorylated by a CDK, an in vitro assay was performed by incubating GST-Mcl-1 with CDK1/cyclin B or CDK2/cyclin A (Fig. 3D) . As assessed by S64 phospho-immunoblot analysis, both CDK1 and CDK2 directly phosphorylated Mcl-1 at S64. In addition, JNK1 but not JNK2 phosphorylated GST-Mcl-1 under the conditions employed in vitro (Fig. 3D) .
Taken together, these data suggest that CDKs and JNK1 have a role, either direct or indirect, in Mcl-1 phosphorylation at S64.
Cell cycle-dependent S64 phosphorylation in intact cells. The observations using CDK inhibitors and recombinant CDK enzymes suggested that S64 might be phosphorylated in a cell cycle-related manner (43) (44) (45) . To examine this possibility, cells were synchronized at the G1/S boundary by aphidicolin or in G2/M by nocodazole prior to immunoblot analysis for S64 phosphorylation (Fig. 4A and B) . The results showed that S64 was phosphorylated to a greater extent in G2/M phase than at the G1/S boundary (Fig. 4C) . This was consistent with the previous observation of a distinct phosphorylation stimulated in G2/M phase (29), and with the above findings concerning a role for CDKs. When protein synthesis was inhibited with cycloheximide and S peptide-tagged Mcl-1 levels were assessed in whole cell lysates by immunoblotting, neither the half-life of S peptide-tagged S64A nor S64E Mcl-1 was significantly different from that of the wild type protein (Fig. 5) . The half-life of wild type and mutant Mcl-1 proteins was also not significantly different from each other during treatment with the death ligand TRAIL. Thus, mutation of S64 to a non-phosphorylatable or a phosphomimetic amino acid does not alter Mcl-1 half-life despite its location within the PEST region.
Ability to phosphorylate S64 is required for Mcl-1-mediated protection from TRAILmediated apoptosis. Mcl-1 inhibits apoptosis by binding to BH3-only proteins and/or Bak (2-5). Therefore, we initially examined binding of S peptide-tagged S64A and S64E Mcl-1 to various Bcl-2 proteins (Fig. 6) ; wildtype Mcl-1 was not employed for these studies because of its variable phosphorylation status (Fig. 3) . No binding by either mutant to Bcl-2, Bax, or Bid was observed (not shown). The phosphomimetic S64E mutant preferentially bound to Noxa, Bim EL and perhaps Bak (Fig. 6) , suggesting that S64 phosphorylation might enhance the antiapoptotic function of Mcl-1 by altering its binding partners.
Next, we examined the effect of S64 phosphorylation on the antiapoptotic function of Mcl-1. We chose to induce apoptosis using the death ligand TRAIL because Mcl-1 contributes to TRAIL resistance in many cell types, including the human cholangiocarcinoma cell line used for this study (20, (46) (47) (48) . KMCH cholangiocarcinoma cells that were stably transfected with shRNA to diminish endogenous Mcl-1 and render them TRAIL sensitive (20) were subsequently transfected with shRNA-resistant cDNAs encoding S64A, S64E, T163A or wildtype Mcl-1. The resulting stable clones used for this analysis expressed similar levels of wildtype or mutant S peptide-tagged Mcl-1 (Fig. 7A, top panel) . These clones also expressed similar levels of other apoptotic mediators, including Bcl-2, Bcl-x L , Bid, Bim, Bax, Bak, death receptors 4 and 5, cFLIP, and caspase 8 (Fig. 7A) . As previously reported, KMCH sh-Mcl-1 cells were quite sensitive to TRAIL-mediated apoptosis (Fig. 7B, C) . Although transfection with wildtype or T163A Mcl-1 made these cells resistant to TRAILmediated apoptosis, transfection with the S64A mutant did not (Fig. 7B, C) . In contrast, stable transfection with the phosphomimetic S64E mutant conveyed TRAIL resistance (Fig. 7B, C) .
Because the wildtype Mcl-1 was as effective in preventing apoptosis as the S64E mutant, we surmised that wildtype Mcl-1 (S64) was either constitutively phosphorylated, or phosphorylation was induced during TRAIL treatment. Indeed, treatment with TRAIL was associated with enhanced phosphorylation of wildtype Mcl-1 at S64 (Fig 7 D) . Basal S64 phosphorylation of Mcl-1 was again decreased with both a JNK inhibitor (SP600125) and a CDK inhibitor (SU9156). Phosphorylation of Mcl-1 at S64 in TRAIL-treated cells was also decreased by both inhibitors with the least phospho-S64-Mcl-1 detected in SU9156-treated cells in the presence of TRAIL (Fig. 7E) .
Pharmacological inhibition of Mcl-1 S64 phosphorylation enhances TRAIL sensitivity. Collectively, the results in Fig. 7 indicate that inability to phosphorylate S64 diminishes the antiapoptotic function of Mcl-1. As an extension of these observations, we predicted that pharmacological inhibition of S64 phosphorylation would also diminish the antiapoptotic function of Mcl-1. To test this possibility, we examined the effect of combining SU9516, which we already demonstrated inhibits Mcl-1 S64 phosphorylation (Figs. 3 & 7) , with TRAIL. For these experiments, parental KMCH cells were treated for 4 h with 10 μM SU9516, a time and concentration that does not diminish total cellular Mcl-1 levels (Fig. 8A ). As indicated using two different assays (Fig. 8A, B) , treatment with SU9516 sensitized the cells to TRAIL-induced apoptosis. In contrast, the ERK pathway inhibitor PD98059 and the CDK5 inhibitor PNU112455A, which do not affect S64 phosphorylation, did not affect TRAIL sensitivity.
DISCUSSION
The However, T163 phosphorylation also renders Mcl-1 a substrate for GSK-3β-mediated phosphorylation of S159 (8); and this dual phosphorylation then facilitates Mcl-1 ubiquitylation, presumably by MULE and/or other E3 ligases, which accelerates Mcl-1 degradation by the proteasome (11) .
JNKmediated S121 phosphorylation reduces the antiapoptotic function of Mcl-1 against cell death by oxidative stress (36) .
To identify additional phosphorylation sites, we performed tandem mass spectrometry on tryptic digests of S peptide-tagged Mcl-1 T163A, a mutant that cannot be phosphorylated on either T163 or S159.
This analysis revealed an additional phosphorylation site at S64, which is within the upstream regulatory half of the Mcl-1 protein. Our subsequent data suggest that S64 is phosphorylated in a manner that can be regulated by the cell cycle. Although S64 was within a potential consensus recognition motif for several kinases, phosphorylation at this site in situ was inhibited by the CDK inhibitors SU9516, olomoucine and roscovitine, but not by the GSK3β inhibitor BIO or the MEK inhibitors PD098059 or U0126. Both CDK1 and CDK2 were capable of directly phosphorylating Mcl-1 at S64 under cellfree conditions. Phosphorylation at this site was greater in cells in G2/M phase as compared to G1/S phase of the cell cycle, which is also consistent with a role for CDK1 and/or CDK2. We recognize that kinase inhibitors may potentially have non-specific effects, therefore the identification of CDK1 and 2 as Mcl-1 S64 phosphorylating enzymes is correlative, but consistent with the observed cell-cycle dependent phosphorylation.
Because S64 is adjacent to P65, this site might also be a substrate for proline-directed kinases, such as JNK. Indeed, JNK1 phosphorylates S64 in vitro (Fig. 3D) , and the JNK pathway inhibitor SP600125 decreased basal S64 phosphorylation in culture (Fig. 3C) . Moreover, TRAIL treatment, which is known to activate JNK is some model systems, induces S64 phosphorylation (Fig. 7D) .
Depending on the site modified, Mcl-1 phosphorylation has previously been shown to either prolong or shorten the half-life of Mcl-1 (6, 8) .
However, the half-life of the nonphosphorylatable Mcl-1 S64A mutant was virtually identical to that of wild type Mcl-1 in a human cholangiocarcinoma cell line (Fig. 5) . Although S64 is within the upstream regulatory portion of Mcl-1 (amino acids 1-176 of human Mcl-1), it lies in a sequence categorized as a "poor" PEST sequence (by PESTFIND), whereas T163 and S159 are in region containing strong potential PEST sequences (residues 104-176) (6). This might explain why phosphorylation of S64 fails to affect the half-life of Mcl-1. Consistent with these observations, immunoblot analysis of affinity purified Mcl-1 also did not detect any difference in the amount of ubiquitinylation for wildtype Mcl-1 vs. the S64A mutant (data not shown). S64E Mcl-1, which binds increased amounts of Noxa (Fig. 6) , also has the same halflife as wild type and S64A Mcl-1 (Fig. 5B) . Noxa has previously been reported to bind Mcl-1 (4,49) and target it for degradation in certain model systems (2) . The unaltered half-life of S64E Mcl-1 suggests that the effect of Noxa on Mcl-1 degradation might be cell-type and context specific.
We and others have previously reported that Mcl-1 plays a pivotal role in resistance to TRAIL-mediated apoptosis in certain cell types (7, 20, 48) . In the cholangiocarcinoma cells utilized in the present study, depletion of Mcl-1 by shRNA enhances TRAIL sensitivity; and expression of shRNA-resistant wildtype Mcl-1 restores TRAIL resistance.
Importantly, the phosphomimetic S64E mutant also confers TRAIL resistance, whereas the non-phosphorylatable S64A Mcl-1 mutant does not (Fig. 7) . The observation that TRAIL induces phosphorylation of S64 (Fig. 7D) likely helps explain why wildtype and S64E Mcl-1 give rise to similar pro-survival activity during exposure to TRAIL. Collectively, these data suggest that S64 phosphorylation enhances the antiapoptotic activity of Mcl-1.
Mcl-1 is thought to inhibit apoptosis by sequestering the proapoptotic BH3-only proteins and/or binding the proapoptotic multidomain Bcl-2 protein Bak (5). Consistent with these current concepts, the phosphomimetic S64E Mcl-1 showed enhanced binding to the BH3-only proteins Noxa and Bim as well as increased binding to Bak compared to the S64A mutant protein (Fig. 6 ). This increased binding occurred without any apparent alteration in the mitochondrial localization of Mcl-1 (data not shown). Although Mcl-1 binding to Bim and Bak and their roles in TRAIL-mediated apoptosis are well established (48, 50) , a role for Noxa in TRAIL-mediated apoptosis has not been reported. The current data suggest that S64E Mcl-1 may protect against cell death, in part, by sequestering Noxa. Based on these results, further experiments to examine the role of Noxa and other BH3-only polypeptides in TRAIL-induced apoptosis appear to be warranted.
Mcl-1, in our system, bound to the proapoptotic protein Bak, but not to Bax. Mcl-1 has been reported to bind to Bax using the yeast twohybrid method (51) , but in mammalian cells, the results have been controversial. Several authors failed to observe binding (2,52,53) consistent with our results while others have reported an interaction (49,51); one group described an interaction between recombinant Mcl-1 and in vitro translated Bax in a cell-free system but found that Mcl-1 and Bax did not interact in cells (54) . The reported difference likely reflects variations between cell types, cell context, and the apoptotic stimulus.
Comparison of Mcl-1 sequences from different species (Fig. 2B) indicates that S64 is conserved among humans, cat and dogs. In mice and rats, on the other hand, this region of the sequence contains two acidic residues, glutamate and aspartate (Fig. 2B) , creating an ortholog that could conceivably act like the S64E version of the human polypeptide. While it is possible that a different serine or threonine in the mouse/rat Mcl-1 might serve the same regulatory function, it is also possible that control of Mcl-1 function by S64 phosphorylation is a relatively recent evolutionary addition to the regulation of apoptosis.
Based on the observation that the nonphosphorylatable S64A mutant fails to protect cells as effectively as wildtype Mcl-1 (Fig. 7B &  C) , we hypothesized that pharmacological inhibition of Mcl-1 phosphorylation might augment the action of apoptotic stimuli that are modulated by Mcl-1. As a preliminary test of this concept, we examined the effect of combining SU9516, which inhibits Mcl-1 phosphorylation at S64 (Fig. 3B) , with TRAIL, which is strongly affected by Mcl-1 expression in KMCH cells (Fig.  7) . As predicted by the analysis of Mcl-1 mutants, SU9516 enhanced TRAIL-mediated apoptosis under conditions where Mcl-1 phosphorylation was diminished but Mcl-1 polypeptide levels were not (Fig. 8) . Although the enhancement of TRAIL cytotoxicity by SU9516 might be greater than expected from the proportion of cells in the cell cycle phases where Mcl-1 is maximally phosphorylated by CDKs, perturbations of the cell cycle, as occurs with CDK inhibitors, have previously been shown to sensitize cells to TRAIL, likely accounting for this observation (55) . However, because we cannot rule out the possibility that SU9516 is enhancing the cytotoxicity of TRAIL by affecting phosphorylation of some other substrate in place of (or in addition to) Mcl-1, further study with additional inhibitors and additional model systems will be required to establish whether inhibition of S64 Mcl-1 phosphorylation is truly an effective strategy for sensitizing tumors that overexpress this apoptotic regulator.
Nonetheless, these preliminary observations raise the possibility that inhibition of Mcl-1 phosphorylation using kinase inhibitors might be a way of enhancing TRAIL sensitivity in cancers characterized by Mcl-1 overexpression. Fig. 1 Western blot signals were quantified and the ratio of the signal from S64E pulldown to S64A pulldown is presented in a column to the right of the blots. were resolved by SDS-PAGE and subjected to immunoblot analysis for the indicated polypeptides. Equal protein loading was verified by blotting for actin. Note that the relative levels of Bcl-2, Bcl-x L , Bid, Bim, Bax, Bak, DR4, DR5, caspase 8, and cFLIP were similar among the clones. B and C: The cell lines described above were incubated in the presence or absence of TRAIL (5 ng/ml) for 4 hours. Apoptosis was evaluated by DAPI staining and fluorescence microscopy (B). Caspase 3/7 activity was measured as described under Materials and Methods (C). D: The effect of TRAIL treatment (5 ng/mL) on Mcl-1 phosphorylation was determined after 0-6 hours of treatment. After enrichment on S protein-agarose beads, proteins were probed by immunoblot for total Mcl-1 and phospho-S64--Mcl-1. E: Cells overexpressing S peptide-tagged WT Mcl-1 were pretreated for 1 hour with SP600125 (20 μM) or SU9516 (10 μM) followed by TRAIL treatment (5 ng/mL) for 4 hours. Enrichment on S protein-agarose was followed by SDS-PAGE and immunoblot for phospho-S64-Mcl-1 or total Mcl-1. Ratios of the band intensity of phospho-over total Mcl-1 are indicated. Apoptosis and caspase 3/7 activity data are expressed as average +/-standard error from four individual experiments. *, p<0.001. (PD, 50 µM), and PNU112455A (PNU, 100 µM) or vehicle (Veh) with or without TRAIL (1 ng/ml) for 8 hours. Apoptosis was evaluated by DAPI staining and fluorescence microscopy (A), and quantitation of caspase 3/7 activity (B). Caspase 3/7 activity was measured as described under Materials and Methods. Note that SU, which sensitized KMCH cells to TRAIL, did not alter total Mcl-1 polypeptide levels (insert). All data were expressed as average +/-standard error from four individual experiments. *, p<0.001 vs vehicle.
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